Diminazene aceturate improves cardiac fibrosis and diastolic dysfunction in rats with kidney disease

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Velkoska, Elena ^a   Patel, Sheila K ^a   Griggs, Karen ^a   Burrell, Louise M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; UNCLASSIFIED DRUG; DIMINAZENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; OUTCOME ASSESSMENT; RAT; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; CARDIAC MUSCLE; COMPLICATION; DRUG EFFECTS; FIBROSIS; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD PRESSURE; DIMINAZENE; FEMALE; FIBROSIS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84992416326     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161760     Document Type: Article

References (39)

1. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80(1):17-28. Epub 2010/12/15. doi: 10.1038/ki.2010.483 PMID: 21150873.
2. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007; 116(1):85-97. PMID: 17606856.
3. Candido R, Burrell LM, Jandeleit-Dahm K, Cooper ME. Vasoactive peptides and the kidney. In: Brenner BM, Rector FC, editors. Brenner & Rector's The Kidney. 8 ed. Philadelphia: Saunders; 2008. p. 333-62.
4. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158 (11):825-30. Epub 2013/06/05. 1691737 [pii] doi: 10.7326/0003-4819-158-11-201306040-00007 PMID: 23732715.
5. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000; 87(5):E1-9. PMID: 10969042.
6. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000; 275(43):33238-43. PMID: 10924499.
7. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention of angiotensin IIinduced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007; 292(2): H736-42. PMID: 17098828.
8. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006; 290(6):H2417-23. PMID: 16415071.
9. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int. 2001; 60(2):715-21. PMID: 11473654.
10. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol. 2001; 21(6):554-62. PMID: 11709803.
11. Taal MW, Brenner BM. Adaptation to nephron loss. In: Brenner BM, Rector FC, editors. Brenner and Rector's The Kidney. 8. Philadelphia: Saunders; 2008. p. 783-819.
12. Velkoska E, Dean RG, Burchill LJ, Levidiotis V, Burrell LM. Reduction in renal ACE2 expression in subtotal nephrectomy is ameliorated with ACE inhibition. Clin Sci (Lond). 2010; 118(4):269-79. Epub 2009/08/25. CS20090318 [pii] doi: 10.1042/CS20090318 PMID: 19698082.
13. Velkoska E, Patel SK, Griggs K, Pickering RJ, Tikellis C, Burrell LM. Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. PLoS One. 2015; 10(3):e0118758. Epub 2015/03/19. doi: 10.1371/journal.pone.0118758 PMID: 25786223.
14. Burrell LM, Burchill L, Dean RG, Griggs K, Patel SK, Velkoska E. Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp Physiol. 2012; 97(4):477-85. Epub 2011/12/27. doi: 10.1113/expphysiol. 2011.063156 PMID: 22198016.
15. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011; 16(8):878-85. Epub 2011/08/24. 1087057111413919 [pii] doi: 10.1177/1087057111413919 PMID: 21859683.
16. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension. 2011; 57(2):314-22. Epub 2010/12/30. [pii] doi: 10.1161/HYPERTENSIONAHA.110.164244 PMID: 21189404.
17. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010; 59(2):529-38. PMID: 19934006. doi: 10.2337/db09-1218
18. Malek M, Nematbakhsh M. The preventive effects of diminazene aceturate in renal ischemia/reperfusion injury in male and female rats. Adv Prev Med. 2014; 2014:740647. Epub 2014/12/06. doi: 10.1155/2014/740647 PMID: 25478235; PubMed Central PMCID: PMC4247946.
19. Burchill L, Velkoska E, Dean RG, Lew RA, Smith AI, Levidiotis V, et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol. 2008; 93(5):622-30. doi: 10.1113/expphysiol.2007.040386 PMID: 18223026.
20. Velkoska E, Dean RG, Griggs K, Burchill LJ, Burrell LM. Angiotensin 1-7 infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond). 2011; 120(8):335-45. Epub 2010/11/26. CS20100280 [pii] doi: 10.1042/CS20100280 PMID: 21091432.
21. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005; 280(34):30113-9. PMID: 15983030.
22. Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension. 2013; 62(4):746-52. Epub 2013/08/21. [pii] doi: 10.1161/HYPERTENSIONAHA.113. 01337 PMID: 23959549.
23. Shenoy V, Gjymishka A, Yagna J, Qi Y, Afzal A, Rigatto K, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013; 187(6):648-57. Epub 2013/02/02. [pii] doi: 10.1164/rccm.201205-0880OC PMID: 23370913.
24. Kennedy DJ, Elkareh J, Shidyak A, Shapiro AP, Smaili S, Mutgi K, et al. Partial nephrectomy as a model for uremic cardiomyopathy in the mouse. Am J Physiol Renal Physiol. 2008; 294(2):F450-4. PMID: 18032546.
25. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005; 26(4):369-75; discussion 22-4. PMID: 15671045.
26. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM, et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem. 2005; 53(10):1245-56. PMID: 15956033.
27. Lew RA, Warner FJ, Hanchapola I, Smith AI. Characterization of angiotensin converting enzyme-2 (ACE2) in human urine. Int J Pept Res Ther. 2006; 12(3):283-9.
28. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes. 2008; 57(4):1018-25. PMID: 18235039. doi: 10.2337/db07-1212
29. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc. 2002; 124(40):11852-3. Epub 2002/10/03. PMID: 12358520.
30. Lai ZW, Hanchapola I, Steer DL, Smith AI. Angiotensin-Converting Enzyme 2 Ecotodomain Shedding Cleavage-Site Identification: Determinants and Constraints. Biochemistry. 2011. Epub 2011/05/14. doi: 10.1021/bi200525y PMID: 21563828.
31. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004; 15(4):166-9. PMID: 15109615.
32. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417(6891):822-8. PMID: 12075344.
33. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014; 66C:167-76. Epub 2013/12/18. doi: 10.1016/j.yjmcc.2013.11.017 PMID: 24332999.
34. Thatcher SE, Zhang X, Howatt DA, Yiannikouris F, Gurley SB, Ennis T, et al. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2014; 34(12):2617-23. Epub 2014/10/11. doi: 10.1161/ATVBAHA.114. 304613 PMID: 25301841; PubMed Central PMCID: PMC4250973.
35. Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014; 63(4):774-82. Epub 2014/01/22. doi: 10.1161/hypertensionaha.113.02856 PMID: 24446061.
36. Raffai G, Khang G, Vanhoutte PM. Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting ACE1. J Cardiovasc Pharmacol. 2014; 63(5):453-60. Epub 2014/01/07. doi: 10.1097/fjc.0000000000000069 PMID: 24390175.
37. Ruebush TK 2nd, Rubin RH, Wolpow ER, Cassaday PB, Schultz MG. Neurologic complications following the treatment of human Babesia microti infection with diminazene aceturate. Am J Trop Med Hyg. 1979; 28(2):184-9. Epub 1979/03/01. PMID: 572145.
38. Homeida AM, El Amin EA, Adam SE, Mahmoud MM. Toxicity of diminazene aceturate (Berenil) to camels. J Comp Pathol. 1981; 91(3):355-60. Epub 1981/07/01. PMID: 6274924.
39. Sharma SP, Bansal GC. Chemoprophylaxis with diminazene aceturate in experimental Babesia bigemina infection in cattle. Res Vet Sci. 1984; 37(1):126-7. Epub 1984/07/01. PMID: 6473911.